Unfavorable social determinants of health are associated with higher burden of financial toxicity among patients with atherosclerotic cardiovascular disease in the US: findings from the National Health Interview Survey.

Cardiovascular disease Disparities Equity Financial toxicity Social determinants of health

Journal

Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826

Informations de publication

Date de publication:
06 Dec 2022
Historique:
received: 05 04 2022
accepted: 10 10 2022
entrez: 6 12 2022
pubmed: 7 12 2022
medline: 7 12 2022
Statut: epublish

Résumé

Atherosclerotic cardiovascular disease (ASCVD) is a major cause of financial toxicity, defined as excess financial strain from healthcare, in the US. Identifying factors that put patients at greatest risk can help inform more targeted and cost-effective interventions. Specific social determinants of health (SDOH) such as income are associated with a higher risk of experiencing financial toxicity from healthcare, however, the associations between more comprehensive measures of cumulative social disadvantage and financial toxicity from healthcare are poorly understood. Using the National Health Interview Survey (2013-17), we assessed patients with self-reported ASCVD. We identified 34 discrete SDOH items, across 6 domains: economic stability, education, food poverty, neighborhood conditions, social context, and health systems. To capture the cumulative effect of SDOH, an aggregate score was computed as their sum, and divided into quartiles, the highest (quartile 4) containing the most unfavorable scores. Financial toxicity included presence of: difficulty paying medical bills, and/or delayed/foregone care due to cost, and/or cost-related medication non-adherence. Approximately 37% of study participants reported experiencing financial toxicity from healthcare, with a prevalence of 15% among those in SDOH Q1 vs 68% in SDOH Q4. In fully-adjusted regression analyses, individuals in the 2nd, 3rd and 4th quartiles of the aggregate SDOH score had 1.90 (95% CI 1.60, 2.26), 3.66 (95% CI 3.11, 4.35), and 8.18 (95% CI 6.83, 9.79) higher odds of reporting any financial toxicity from healthcare, when compared with participants in the 1st quartile. The associations were consistent in age-stratified analyses, and were also present in analyses restricted to non-economic SDOH domains and to 7 upstream SDOH features. An unfavorable SDOH profile was strongly and independently associated with subjective financial toxicity from healthcare. This analysis provides further evidence to support policies and interventions aimed at screening for prevalent financial toxicity and for high financial toxicity risk among socially vulnerable groups.

Sections du résumé

BACKGROUND BACKGROUND
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of financial toxicity, defined as excess financial strain from healthcare, in the US. Identifying factors that put patients at greatest risk can help inform more targeted and cost-effective interventions. Specific social determinants of health (SDOH) such as income are associated with a higher risk of experiencing financial toxicity from healthcare, however, the associations between more comprehensive measures of cumulative social disadvantage and financial toxicity from healthcare are poorly understood.
METHODS METHODS
Using the National Health Interview Survey (2013-17), we assessed patients with self-reported ASCVD. We identified 34 discrete SDOH items, across 6 domains: economic stability, education, food poverty, neighborhood conditions, social context, and health systems. To capture the cumulative effect of SDOH, an aggregate score was computed as their sum, and divided into quartiles, the highest (quartile 4) containing the most unfavorable scores. Financial toxicity included presence of: difficulty paying medical bills, and/or delayed/foregone care due to cost, and/or cost-related medication non-adherence.
RESULTS RESULTS
Approximately 37% of study participants reported experiencing financial toxicity from healthcare, with a prevalence of 15% among those in SDOH Q1 vs 68% in SDOH Q4. In fully-adjusted regression analyses, individuals in the 2nd, 3rd and 4th quartiles of the aggregate SDOH score had 1.90 (95% CI 1.60, 2.26), 3.66 (95% CI 3.11, 4.35), and 8.18 (95% CI 6.83, 9.79) higher odds of reporting any financial toxicity from healthcare, when compared with participants in the 1st quartile. The associations were consistent in age-stratified analyses, and were also present in analyses restricted to non-economic SDOH domains and to 7 upstream SDOH features.
CONCLUSIONS CONCLUSIONS
An unfavorable SDOH profile was strongly and independently associated with subjective financial toxicity from healthcare. This analysis provides further evidence to support policies and interventions aimed at screening for prevalent financial toxicity and for high financial toxicity risk among socially vulnerable groups.

Identifiants

pubmed: 36474300
doi: 10.1186/s13690-022-00987-z
pii: 10.1186/s13690-022-00987-z
pmc: PMC9727868
doi:

Types de publication

Journal Article

Langues

eng

Pagination

248

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Am J Prev Cardiol. 2020 Jul 13;2:100034
pubmed: 34327457
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
J Am Coll Cardiol. 2019 Feb 19;73(6):727-732
pubmed: 30765039
Circulation. 2021 Jan 19;143(3):244-253
pubmed: 33269599
Support Care Cancer. 2018 Apr;26(4):1265-1272
pubmed: 29105024
J Am Heart Assoc. 2020 Oct 20;9(19):e017793
pubmed: 32924728
Circulation. 2019 Dec 17;140(25):2067-2075
pubmed: 31760784
J Health Care Poor Underserved. 2020;31(2):1018-1035
pubmed: 33410822
Clin J Oncol Nurs. 2019 Oct 1;23(5):14-18
pubmed: 31538990
JAMA Health Forum. 2020 Jul 1;1(7):e200879
pubmed: 36218692
J Clin Oncol. 2016 Jan 20;34(3):259-67
pubmed: 26644532
Circulation. 2016 May 3;133(18):e615-53
pubmed: 27045139
Am J Med. 2020 Oct;133(10):e541-e543
pubmed: 32442515
Am J Kidney Dis. 2021 Nov;78(5):658-668
pubmed: 34144103
JACC CardioOncol. 2021 Jun 15;3(2):236-246
pubmed: 34396329
BMC Cardiovasc Disord. 2017 Feb 14;17(1):61
pubmed: 28196528
Circulation. 2018 May 15;137(20):2166-2178
pubmed: 29760227
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e006139
pubmed: 32069093
Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):143-53
pubmed: 26941417
CA Cancer J Clin. 2018 Mar;68(2):153-165
pubmed: 29338071
J Am Heart Assoc. 2019 Dec 17;8(24):e008831
pubmed: 31838970
Stroke. 2020 Aug;51(8):2445-2453
pubmed: 32673521
JAMA Cardiol. 2018 Aug 1;3(8):729-738
pubmed: 29971325
Diabetes Care. 2017 Feb;40(2):239-245
pubmed: 27956384
JAMA Cardiol. 2021 Jun 1;6(6):713-717
pubmed: 33325991
Health Aff (Millwood). 2013 Aug;32(8):1361-7
pubmed: 23918479
JAMA Cardiol. 2021 Jan 1;6(1):87-91
pubmed: 32902562
Int J Health Serv. 2016 Oct;46(4):693-711
pubmed: 27496545

Auteurs

Javier Valero-Elizondo (J)

Department of Cardiology, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart & Vascular Center, 7550 Greenbriar Drive, Houston, TX, 77030, USA. zjaved@houstonmethodist.org.
Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA. zjaved@houstonmethodist.org.

Zulqarnain Javed (Z)

Department of Cardiology, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart & Vascular Center, 7550 Greenbriar Drive, Houston, TX, 77030, USA.
Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA.

Rohan Khera (R)

Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA.

Mauricio E Tano (ME)

Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA.

Ramzi Dudum (R)

Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.

Isaac Acquah (I)

Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA.

Adnan A Hyder (AA)

Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

Julia Andrieni (J)

Population Health and Primary Care, Houston Methodist Hospital, Houston, TX, USA.

Garima Sharma (G)

Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Michael J Blaha (MJ)

Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA.

Salim S Virani (SS)

Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX, USA.
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA.

Ron Blankstein (R)

Cardiovascular Imaging Program, Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.

Miguel Cainzos-Achirica (M)

Department of Cardiology, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart & Vascular Center, 7550 Greenbriar Drive, Houston, TX, 77030, USA.
Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA.

Khurram Nasir (K)

Department of Cardiology, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart & Vascular Center, 7550 Greenbriar Drive, Houston, TX, 77030, USA.
Center for Outcomes Research, Houston Methodist, 7550 Greenbriar Drive, Houston, TX, 77030, USA.

Classifications MeSH